SCHEMBL23501736

SCHEMBL23501736

c1ccc(Oc2ccc3ccncc3c2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IKBKB O14920 2/20 0.48
LMNA P02545 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
MRGPRX4 Q96LA9 1/20 0.47
ABL1 P00519 2/20 0.45
SIRT2 Q8IXJ6 1/20 0.44
SIRT1 Q96EB6 1/20 0.44
SIRT3 Q9NTG7 1/20 0.44
CLK1 P49759 1/20 0.44
LTA4H P09960 1/20 0.43
TSHR P16473 1/20 0.43
HAO1 Q9UJM8 1/20 0.42
CYP3A4 P08684 1/20 0.42
PRKCZ Q05513 1/20 0.42
IMPDH2 P12268 1/20 0.42
HASPIN Q8TF76 1/20 0.42
CYP11B1 P15538 1/20 0.41
CYP11B2 P19099 1/20 0.41
TRPV6 Q9H1D0 1/20 0.41
RAB9A P51151 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26511137 0.95 TDP1 (0.48) IKBKBLMNATDP1MRGPRX4ABL1
SCHEMBL15271125 0.84 RAB9A (0.51) IKBKBCYP3A4CYP11B1CYP11B2RAB9A
SCHEMBL9515088 0.80 LTA4H (0.60) LTA4HTSHRRAB9A
SCHEMBL4402154 0.80 LTA4H (0.60) TDP1LTA4HTSHRHAO1
SCHEMBL29860094 0.80 LTA4H (0.60) TDP1LTA4HTSHRHAO1
SCHEMBL3992804 0.80 RAB9A (0.46) IKBKBPRKCZRAB9A
SCHEMBL9789564 0.80 LTA4H (0.67) TDP1LTA4HTSHRRAB9A
SCHEMBL14418573 0.79 LTA4H (0.48) TDP1ABL1SIRT2SIRT1SIRT3
SCHEMBL7434265 0.79 GAA (0.45) IKBKBLMNAMRGPRX4SIRT2SIRT1
SCHEMBL7384741 0.79 NOTUM (0.52) IKBKBTSHRCYP3A4IMPDH2CYP11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12612367-B2 Method for producing nitrogen-containing heteroarylcarboxamide acetic acid derivative AKEBIA THERAPEUTICS, INC. (US) 2026-04-28 US claimed
US-20230159462-A1 METHOD FOR PRODUCING NITROGEN-CONTAINING HETEROARYLCARBOXAMIDE ACETIC ACID DERIVATIVE KREOS CAPITAL VII (UK) LIMITED (GB) 2023-05-25 US claimed
WO-2021117767-A1 METHOD FOR PRODUCING NITROGEN-CONTAINING HETEROARYLCARBOXAMIDE ACETIC ACID DERIVATIVE 田辺三菱製薬株式会社 2021-06-17 WO claimed
US-12612367-B2 Method for producing nitrogen-containing heteroarylcarboxamide acetic acid derivative AKEBIA THERAPEUTICS, INC. (US) 2026-04-28 US disclosed
US-20230159462-A1 METHOD FOR PRODUCING NITROGEN-CONTAINING HETEROARYLCARBOXAMIDE ACETIC ACID DERIVATIVE KREOS CAPITAL VII (UK) LIMITED (GB) 2023-05-25 US disclosed
WO-2021117767-A1 METHOD FOR PRODUCING NITROGEN-CONTAINING HETEROARYLCARBOXAMIDE ACETIC ACID DERIVATIVE 田辺三菱製薬株式会社 2021-06-17 WO disclosed
CN-101394843-A Improved anemia treatment using HIF alpha stabilizers FIBROGEN INC (US) 2009-03-25 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12612367-B2 Method for producing nitrogen-containing heteroarylcarboxamide acetic acid derivative DIMT1, HIF1A, HIF1AN IKBKB 2546/4885LMNA 2985/4885TDP1 3467/4885
US-20230159462-A1 METHOD FOR PRODUCING NITROGEN-CONTAINING HETEROARYLCARBOXAMIDE ACETIC ACID DERIVATIVE DIMT1, DLAT, COASY IKBKB 1936/4885LMNA 2990/4885TDP1 2984/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.